NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix provides business update and reports financial results for the first half of 2021
    Nanobiotix provides second quarter operational and financial update
    Nanobiotix Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer



    September 20, 2021

    BioPharm America™ 2021

    More info
    September 14, 2021

    ImmunoRad 2021

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation